Profusa (PFSA) Plunges Following 1-for-25 Reverse Stock Split Announcement

Profusa Inc. (PFSA), a digital health company, announced that it will implement a one-for-twenty-five (1:25) reverse stock split, effective July 7, 2026. This action is intended to increase the per-share trading price of its common stock and ensure compliance with Nasdaq's minimum bid price requirement. Following the announcement, the company's shares experienced a significant drop of over 28% on the day.

According to Profusa's statement, the reverse stock split will take effect at 12:01 a.m. Eastern Time on Tuesday, July 7, 2026. Trading on a post-split basis will commence on The Nasdaq Global Market on the same day. The existing ticker symbol “PFSA” will remain unchanged, but the shares will trade under a new CUSIP number, 74319X 306. As a result of the split, the number of outstanding common shares will be reduced from approximately 13.2 million to about 530,000, while the number of authorized shares will remain constant at 601 million.

The company further noted that no fractional shares would be issued as a result of the reverse stock split; instead, stockholders entitled to fractional shares will receive a cash payment in lieu thereof. This marks Profusa’s second reverse stock split this year, following a 1-for-75 reverse split that became effective less than five months ago, on February 9, 2026. This sequence of events highlights the company's persistent challenges in maintaining its share price above the critical $1 threshold.

Profusa shares fell below $1 on April 10 and have since failed to surpass that level. Nasdaq listing rules mandate that companies maintain a minimum bid price of $1 per share; failure to do so for an extended period can lead to delisting from the exchange. The decision to execute another reverse stock split is therefore a direct measure to address this delisting risk and regain compliance.

Financial analysts have pointed out that Profusa is rapidly consuming cash, and its financial health is rated as “WEAK” by InvestingPro analysis. Prior to the reverse split announcement, the company's market capitalization stood at approximately $610,000, with its stock trading around $0.09. Concurrently, Profusa has been pursuing strategic initiatives, including the approval of plans to acquire the PanOmics molecular diagnostics platform from BioInsights for approximately $30 million. This acquisition aims to expand the company's diagnostic capabilities and support new applications, such as pancreatic cancer monitoring.

Market expectations suggest that while the reverse stock split may temporarily boost the share price, a sustainable recovery could be challenging unless the company addresses its underlying financial issues. Analysts emphasize that such splits often fall short of significantly enhancing investor confidence, urging Profusa to present a robust strategy for sustainable growth and profitability. The integration of the PanOmics platform and future product launches will be closely monitored for their impact on the company's performance.